Dr. Mary Claire Haver

But we are not comfortable with the safety data.

We do not have enough safety data to prove that it doesn't cause breast cancer, for example.

Now, remember, this was in the aftermath of the WHI.

Viagra had six months of safety data, just to whisper that there.

We've covered that ad nauseum on this podcast.

podcast, but say it again.

I'll say it again.

People died in the Viagra trials, but we did not.

We did not.

People have died from Viagra.

I will say as being married to a urologist who also focuses in sexual medicine.

We have wonderfully robust debates when I talk about this because he will definitely argue on behalf of men and their sexual function.

And I have a lot of empathy for what it means for men after going to all these sexual medicine meetings.

And I have even more for women because we can't get a product approved because we have to prove that it doesn't cause breast cancer.

The amount of money that would be needed to do that when in the patch studies, there was no increased risk of breast cancer.

We have lots of data showing actually that it doesn't seem to increase the risk of breast cancer.

Either way, what's so interesting is there was a company that then said, OK, we will do this.

We will pay for the study that is required to show that there is not a signal for breast cancer, that it is safe.

And it was a gel.

It was a 1% gel.